Issue 47, 2025, Issue in Progress

Correction: LC-MS/MS characterization of pirtobrutinib impurities and product degradation: stability studies

Abstract

Correction for ‘LC-MS/MS characterization of pirtobrutinib impurities and product degradation: stability studies’ by Modachakanahally K. Pavithra et al., RSC Adv., 2024, 14, 34868–34882, https://doi.org/10.1039/D4RA06299J.

Associated articles

Article information

Article type
Correction
Submitted
10 Oct 2025
Accepted
10 Oct 2025
First published
20 Oct 2025
This article is Open Access
Creative Commons BY license

RSC Adv., 2025,15, 39539-39539

Correction: LC-MS/MS characterization of pirtobrutinib impurities and product degradation: stability studies

M. K. Pavithra, C. G., H. N. Deepakumari, H. D. Revanasiddappa, S. J. Mohammed, H. Sh. Majdi, A. H. Alsabhan and S. J. Ukkund, RSC Adv., 2025, 15, 39539 DOI: 10.1039/D5RA90116B

This article is licensed under a Creative Commons Attribution 3.0 Unported Licence. You can use material from this article in other publications without requesting further permissions from the RSC, provided that the correct acknowledgement is given.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements